brryh, yes, with a "home run", ATH434 will be approved by the...

brryh, yes, with a "home run", ATH434 will be approved by the FDA as is possible with orphan drugs. IMO, this has been the original strategy starting with the MSA population, a small market (estimated to be over 1 billion in 1 year) but not too small to make any money, and very close pathology with PD with a big market. Both phase 2 studies have the same primary outcome measure: change in iron content in the brain measured by MRI. That would be equally good for PD with blood tests of alpha-synuclein and neurofilaments as in these phase 2 studies. A "home run" includes safety.

IMO, the next needed partner is a big pharma (after a home run) and ATH also had a "home run" in the PD ape study. Big pharma has the money to do phase 3. I think that Stanford and Vanderbilt cannot sponsor any big phase 3 studies and even after that, there would be a lack of big pharma to go to the market.

Professor Masters has published papers relating the methodology in finding very early cases of AD. Not a plan yet to get started. He needs a partner and he has a lot of connections, Antibiotic-resistant studies are missing after the first boom of them 3 years ago. There is no news of the promised otitis study by Dr. Neville. Stamler / Queensland cooperation does not seem to work.